Organ Transplant Rejection

HuMax-TAC program announced

Published in Blood Weekly, January 9th, 2003

Genmab, A/S, announced its HuMax-TAC antibody program against the interleukin-2 receptor (IL-2R) target, also known as TAC, for use to treat organ transplant rejection.

Genmab has identified a lead candidate in this program which appears to be superior to at least one antibody product currently on the market when tested in vitro. In these laboratory studies, HuMax-TAC showed superior inhibition of IL-2 binding to the IL-2 receptor and also blocked the proliferation of activated T-cells that express the receptor and play an important role in inflammation. Other potential indications include graft versus host disease, T-cell leukemia, Hodgkin disease, and autoimmune...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-01-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry